Document Type : Review Article


1 Student Research Committee, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran

2 Department of Neurosurgery, Division of Neuro Critical Care, University of Texas Health Science Center at San Antonio School of Medicine, San Antonio, Texas, USA

3 Deccan College of Medical Sciences, Owaisi Hospital and Research Centre, Hyderabad, Telangana State, India

4 Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

5 University of Texas Health Science Center at San Antonio School of Medicine, San Antonio, Texas, USA


Aneurysmal subarachnoid hemorrhage (aSAH) accounts for 2–5% of all strokes, and 10%‐15% of aSAH patients will not survive until hospital admission. Induced hypertension (IH) is an emerging therapeutic option being used for the treatment of vasospasm in aSAH. For patients with cerebral vasospasm (CVS) consequent to SAH, IH is implemented to increase systolic blood pressure (SBP) in order to optimize cerebral blood flow (CBF) and prevent delayed cerebral ischemia (DCI). Prophylactic use of IH has been associated with the development of vasospasm and cerebral ischemia in SAH patients. Various trials have defined several different parameters to help clinicians decide when to initiate IH in a SAH patient. However, there is insufficient evidence to recommend therapeutic IH in aSAH due to the possible serious complications like myocardial ischemia, development of posterior reversible encephalopathy syndrome (PRES), pulmonary edema, and even rupture of another unsecured aneurysm. This narrative review showed the favorable impact of IH therapy on aSAH patients; however, it is crucial to conduct further clinical and molecular experiments to shed more light on the effects of IH in aSAH.


  1. Daou BJ, Koduri S, Thompson BG, Chaudhary N, Pandey AS. Clinical and experimental aspects of aneurysmal subarachnoid hemorrhage. CNS Neurosci Ther 2019; 25(10): 1096-112.
  2. Rincon F, Rossenwasser RH, Dumont A. The epidemiology of admissions of nontraumatic subarachnoid hemorrhage in the United States. Neurosurgery 2013; 73(2): 217-22.
  3. Coulibaly AP, Provencio JJ. Aneurysmal subarachnoid hemorrhage: An overview of inflammation-induced cellular changes. Neurotherapeutics 2020; 17(2): 436-45.
  4. Etminan N, Macdonald RL. Management of aneurysmal subarachnoid hemorrhage. Handb Clin Neurol 2017; 140: 195-228.
  5. Lucke-Wold BP, Logsdon AF, Manoranjan B, Turner RC, McConnell E, Vates GE, et al. Aneurysmal subarachnoid hemorrhage and neuroinflammation: A comprehensive review. Int J Mol Sci 2016; 17(4): 497.
  6. Elsamadicy AA, Koo AB, Reeves BC, Sujijantarat N, David WB, Malhotra A, et al. Posterior reversible encephalopathy syndrome caused by induced hypertension to treat cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage. World Neurosurg 2020; 143: e309-e323.
  7. Neuschmelting V, Fathi AR, Hidalgo Staub ET, Marbacher S, Schroth G, Takala J, et al. Norepinephrine-induced hypertension dilates vasospastic basilar artery after subarachnoid haemorrhage in rabbits. Acta Neurochir (Wien) 2009; 151(5): 487-93.
  8. Otsubo H, Takemae T, Inoue T, Kobayashi S, Sugita K. Normovolaemic induced hypertension therapy for cerebral vasospasm after subarachnoid haemorrhage. Acta Neurochir (Wien) 1990; 103(1-2): 18-26.
  9. Haegens NM, Gathier CS, Horn J, Coert BA, Verbaan D, van den Bergh WM. Induced hypertension in preventing cerebral infarction in delayed cerebral ischemia after subarachnoid hemorrhage. Stroke 2018; 49(11): 2630-6.
  10. Gathier CS, van den Bergh WM, van der Jagt M, Verweij BH, Dankbaar JW, Muller MC, et al. Induced hypertension for delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: A randomized clinical trial. Stroke 2018; 49(1): 76-83.
  11. Dabus G, Nogueira RG. Current options for the management of aneurysmal subarachnoid hemorrhage-induced cerebral vasospasm: A comprehensive review of the literature. Interv Neurol 2013; 2(1): 30-51.
  12. Angermann M, Jablawi F, Keulers A, Angermann M, Schubert GA, Weiss M, et al. Posterior reversible encephalopathy syndrome after induced hypertension therapy for delayed cerebral ischemia after subarachnoid hemorrhage: A case-control study. J Neurol Sci 2021; 421: 117313.
  13. Connolly ES, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: A guideline for healthcare professionals from the American Heart Association/american Stroke Association. Stroke 2012; 43(6): 1711-37.
  14. Loan JJM, Wiggins AN, Brennan PM. Medically induced hypertension, hypervolaemia and haemodilution for the treatment and prophylaxis of vasospasm following aneurysmal subarachnoid haemorrhage: Systematic review. Br J Neurosurg 2018; 32(2): 157-64.
  15. van Haren F, Velloza P, Chan S, Mews P, Lueck CJ. Induced hypertension for preventing complications of delayed cerebral ischaemia in aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2017; 2017(11): CD012842.
  16. Platz J, Guresir E, Vatter H, Berkefeld J, Seifert V, Raabe A, et al. Unsecured intracranial aneurysms and induced hypertension in cerebral vasospasm: Is induced hypertension safe? Neurocrit Care 2011; 14(2): 168-75.
  17. Petruk KC, West M, Mohr G, Weir BK, Benoit BG, Gentili F, et al. Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial. J Neurosurg 1988; 68(4): 505-17.
  18. Onur OA, Fink GR, Kuramatsu JB, Schwab S. Aneurysmatic subarachnoid haemorrhage. Neurol Res Pract 2019; 1: 15.
  19. Weiland J, Beez A, Westermaier T, Kunze E, Siren AL, Lilla N. Neuroprotective strategies in aneurysmal subarachnoid hemorrhage (aSAH). Int J Mol Sci 2021; 22(11): 5442.
  20. Cho WS, Kim JE, Park SQ, Ko JK, Kim DW, Park JC, et al. Korean Clinical Practice Guidelines for Aneurysmal Subarachnoid Hemorrhage. J Korean Neurosurg Soc 2018; 61(2): 127-66.
  21. Harmsen WJ, Ribbers GM, Heijenbrok-Kal MH, Bussmann JBJ, Sneekes EM, Khajeh L, et al. Inactive lifestyles and sedentary behavior in persons with chronic aneurysmal subarachnoid hemorrhage: Evidence from accelerometer-based activity monitoring. J Neuroeng Rehabil 2017; 14(1): 120.
  22. Giordan E, Graffeo CS, Rabinstein AA, Brown RD, Rocca WA, Chamberlain AM, et al. Aneurysmal subarachnoid hemorrhage: Long-term trends in incidence and survival in Olmsted County, Minnesota. J Neurosurg 2020; 134(3): 878-83.
  23. Rouanet C, Silva GS. Aneurysmal subarachnoid hemorrhage: Current concepts and updates. Arq Neuropsiquiatr 2019; 77(11): 806-14.
  24. Etminan N, Chang HS, Hackenberg K, de Rooij NK, Vergouwen MDI, Rinkel GJE, et al. Worldwide incidence of aneurysmal subarachnoid hemorrhage according to region, time period, blood pressure, and smoking prevalence in the population: A systematic review and meta-analysis. JAMA Neurol 2019; 76(5): 588-97.
  25. Ohkuma H, Shimamura N, Naraoka M, Katagai T. Aneurysmal subarachnoid hemorrhage in the elderly over age 75: A systematic review. Neurol Med Chir (Tokyo) 2017; 57(11): 575-83.
  26. Ganaw AEA, Tharayil AM, Khair AOMB, Tahseen S, Hassan J, Malmstrom MFA, et al. Aneurysmal subarachnoid hemorrhage. In: Nissar S, editor. Intensive care. Rijeka, Croatia: IntechOpen; 2017.
  27. Ohkuma H, Fujita S, Suzuki S. Incidence of aneurysmal subarachnoid hemorrhage in Shimokita, Japan, from 1989 to 1998. Stroke 2002; 33(1): 195-9.
  28. Rahmanian A, Jamali M, Bagheri LK, Ghahramani S. Aneurysmal subarachnoid haemorrhage (aSAH): Five consecutive years' experience of Fars province, Iran. PLoS One 2017; 12(11): e0189005.
  29. Tada Y, Wada K, Shimada K, Makino H, Liang EI, Murakami S, et al. Roles of hypertension in the rupture of intracranial aneurysms. Stroke 2014; 45(2): 579-86.
  30. Bashir A, Andresen M, Bartek J, Cortsen M, Eskesen V, Wagner A. Intra-arterial nimodipine for cerebral vasospasm after subarachnoid haemorrhage: Influence on clinical course and predictors of clinical outcome. Neuroradiol J 2016; 29(1): 72-81.
  31. Sharma D. Perioperative management of aneurysmal subarachnoid hemorrhage. Anesthesiology 2020; 133(6): 1283-305.
  32. Imamura H, Sakai N, Sakai C, Fujinaka T, Ishii A. Endovascular treatment of aneurysmal subarachnoid hemorrhage in Japanese Registry of Neuroendovascular Therapy (JR-NET) 1 and 2. Neurol Med Chir (Tokyo) 2014; 54(2): 81-90.
  33. Francoeur CL, Mayer SA. Management of delayed cerebral ischemia after subarachnoid hemorrhage. Crit Care 2016; 20(1): 277.
  34. Diringer MN, Bleck TP, Claude HJ 3rd, Menon D, Shutter L, Vespa P, et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: Recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. Neurocrit Care 2011; 15(2): 211-40.
  35. Vatter H, Zimmermann M, Tesanovic V, Raabe A, Schilling L, Seifert V. Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist clinically effective for the treatment of cerebral vasospasm. Part I: Inhibitory effect on endothelin(A) receptor-mediated contraction. J Neurosurg 2005; 102(6): 1101-7.
  36. Miller BA, Turan N, Chau M, Pradilla G. Inflammation, vasospasm, and brain injury after subarachnoid hemorrhage. Biomed Res Int 2014; 2014: 384342.
  37. Hendryk S, Jarzab B, Josko J. Increase of the IL-1 beta and IL-6 levels in CSF in patients with vasospasm following aneurysmal SAH. Neuro Endocrinol Lett 2004; 25(1-2): 141-7.
  38. Chou SH, Feske SK, Simmons SL, Konigsberg RG, Orzell SC, Marckmann A, et al. Elevated peripheral neutrophils and matrix metalloproteinase 9 as biomarkers of functional outcome following subarachnoid hemorrhage. Transl Stroke Res 2011; 2(4): 600-7.
  39. Feiler S, Plesnila N, Thal SC, Zausinger S, Scholler K. Contribution of matrix metalloproteinase-9 to cerebral edema and functional outcome following experimental subarachnoid hemorrhage. Cerebrovasc Dis 2011; 32(3): 289-95.
  40. Hanafy KA. The role of microglia and the TLR4 pathway in neuronal apoptosis and vasospasm after subarachnoid hemorrhage. J Neuroinflammation 2013; 10: 83.
  41. Sun X, Ji C, Hu T, Wang Z, Chen G. Tamoxifen as an effective neuroprotectant against early brain injury and learning deficits induced by subarachnoid hemorrhage: Possible involvement of inflammatory signaling. J Neuroinflammation 2013; 10: 157.
  42. McDowell MM, Ducruet AF. The genetics of aneurysms: A complex pathophysiology requiring complex analysis. World Neurosurg 2015; 83(3): 280-1.
  43. Sathyan S, Koshy LV, Balan S, Easwer HV, Premkumar S, Nair S, et al. Association of Versican (VCAN) gene polymorphisms rs251124 and rs2287926 (G428D), with intracranial aneurysm. Meta Gene 2014; 2: 651-60.
  44. Leclerc JL, Blackburn S, Neal D, Mendez NV, Wharton JA, Waters MF, et al. Haptoglobin phenotype predicts the development of focal and global cerebral vasospasm and may influence outcomes after aneurysmal subarachnoid hemorrhage. Proc Natl Acad Sci USA 2015; 112(4): 1155-60.
  45. Xu M, Sham P, Ye Z, Lindpaintner K, He L. A1166C genetic variation of the angiotensin II type I receptor gene and susceptibility to coronary heart disease: Collaborative of 53 studies with 20,435 cases and 23,674 controls. Atherosclerosis 2010; 213(1): 191-9.
  46. Sun Q, Wu W, Hu YC, Li H, Zhang D, Li S, et al. Early release of high-mobility group box 1 (HMGB1) from neurons in experimental subarachnoid hemorrhage in vivo and in vitro. J Neuroinflammation 2014; 11: 106.
  47. Starke RM, Chalouhi N, Jabbour PM, Tjoumakaris SI, Gonzalez LF, Rosenwasser RH, et al. Critical role of TNF-alpha in cerebral aneurysm formation and progression to rupture. J Neuroinflammation 2014; 11: 77.
  48. Chen S, Ma Q, Krafft PR, Hu Q, Rolland W, Sherchan P, et al. P2X7R/cryopyrin inflammasome axis inhibition reduces neuroinflammation after SAH. Neurobiol Dis 2013; 58: 296-307.
  49. Gathier CS, van den Bergh WM, Slooter AJ. HIMALAIA (Hypertension Induction in the Management of AneurysmaL subArachnoid haemorrhage with secondary IschaemiA): A randomized single-blind controlled trial of induced hypertension vs. no induced hypertension in the treatment of delayed cerebral ischemia after subarachnoid hemorrhage. Int J Stroke 2014; 9(3): 375-80.
  50. Gathier CS, Dankbaar JW, van der Jagt M, Verweij BH, Oldenbeuving AW, Rinkel GJ, et al. Effects of induced hypertension on cerebral perfusion in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: A randomized clinical trial. Stroke 2015; 46(11): 3277-81.
  51. Muehlschlegel S, Dunser MW, Gabrielli A, Wenzel V, Layon AJ. Arginine vasopressin as a supplementary vasopressor in refractory hypertensive, hypervolemic, hemodilutional therapy in subarachnoid hemorrhage. Neurocrit Care 2007; 6(1): 3-10.
  52. Macdonald RL, Rosengart A, Huo D, Karrison T. Factors associated with the development of vasospasm after planned surgical treatment of aneurysmal subarachnoid hemorrhage. J Neurosurg 2003; 99(4): 644-52.
  53. Shibuya M, Suzuki Y, Sugita K, Saito I, Sasaki T, Takakura K, et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg 1992; 76(4): 571-7.
  54. Depret F, Coutrot M. Commentary: Posterior reversible encephalopathy syndrome as a complication of induced hypertension in subarachnoid hemorrhage: A case-control study. Neurosurgery 2019; 85(2): E243-E244.
  55. Hobson EV, Craven I, Blank SC. Posterior reversible encephalopathy syndrome: A truly treatable neurologic illness. Perit Dial Int 2012; 32(6): 590-4.
  56. Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: Associated clinical and radiologic findings. Mayo Clin Proc 2010; 85(5): 427-32.
  57. Allen ML, Kulik T, Keyrouz SG, Dhar R. Posterior Reversible encephalopathy syndrome as a complication of induced hypertension in subarachnoid hemorrhage: A case-control study. Neurosurgery 2019; 85(2): 223-30.
  58. Muizelaar JP, Becker DP. Induced hypertension for the treatment of cerebral ischemia after subarachnoid hemorrhage. Direct effect on cerebral blood flow. Surg Neurol 1986; 25(4): 317-25.
  59. de Winkel J, van der Jagt M, Lingsma HF, Roozenbeek B, Calvillo E, Chou SH, et al. International practice variability in treatment of aneurysmal subarachnoid hemorrhage. J Clin Med 2021; 10(4): 762.
  60. Sakowitz OW, Raabe A, Vucak D, Kiening KL, Unterberg AW. Contemporary management of aneurysmal subarachnoid hemorrhage in Germany: Results of a survey among 100 neurosurgical departments. Neurosurgery 2006; 58(1): 137-45.
  61. Hofman M, Hajder N, Duda I, Krzych LJ. A questionnaire survey of management of patients with aneurysmal subarachnoid haemorrhage in Poland. Int J Environ Res Public Health 2020; 17(11): 4161.
  62. Lee KH, Lukovits T, Friedman JA. "Triple-H" therapy for cerebral vasospasm following subarachnoid hemorrhage. Neurocrit Care 2006; 4(1): 68-76.
  63. Raabe A, Beck J, Berkefeld J, Deinsberger W, Meixensberger J, Schmiedek P, et al. Recommendations for the management of patients with aneurysmal subarachnoid hemorrhage. Zentralbl Neurochir 2005; 66(2): 79-91. [In German].
  64. Raghavan A, Xu J, Wright JM, Wright CH, Miller B, Hu Y. Protective effect of unilateral vasospasm in the setting of HHH-associated posterior reversible encephalopathy syndrome: case report, review of the literature, and treatment considerations. Chin Neurosurg J 2018; 4: 34.
  65. Dhar R, Scalfani MT, Zazulia AR, Videen TO, Derdeyn CP, Diringer MN. Comparison of induced hypertension, fluid bolus, and blood transfusion to augment cerebral oxygen delivery after subarachnoid hemorrhage. J Neurosurg 2012; 116(3): 648-56.
  66. Dankbaar JW, Slooter AJ, Rinkel GJ, Schaaf IC. Effect of different components of triple-H therapy on cerebral perfusion in patients with aneurysmal subarachnoid haemorrhage: A systematic review. Crit Care 2010; 14(1): R23.